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Among US women, breast cancer is the most commonly diagnosed 
cancer and the second most common cause of cancer-related 
deaths (1). Data from the Surveillance, Epidemiology, and End 
Results (SEER) program show that 6.5% of breast cancers are 
diagnosed in women who are younger than 40 years and only 0.6% 
are diagnosed in women who are younger than 30 years (2). 
Among younger women, SEER age-adjusted invasive breast can-
cer incidence rates per 100 000 women in the general population 
are 0.1 cancers for those aged 15–19 years, 0.7 cancers for those 
aged 20–24 years, 3.8 cancers for those aged 25–29 years, 12.9 
cancers for those aged 30–34 years, and 29.3 cancers for those aged 
35–39 years; this rate is 59.1 cancers for women aged 40–44 years 
(2). Breast cancers diagnosed in young women have poorer prog-
nostic characteristics, higher recurrence rates (3), and higher rela-
tive mortality rates than those diagnosed in older women (4,5).
In this study, we defined “young” women as being younger than 
40 years because this age group is excluded from standard guide-
lines for screening mammography in the United States (6–8) and 
other countries (9). Today, the American Cancer Society (1,6), 
Cancer Genetics Studies Consortium (10), and others (11) advo-
cate screening among young women who have a high-risk profile 
or known BRCA1 and/or BRCA2 mutations. In the 1980s, the 
American Cancer Society recommended a baseline mammogram 
for women at average risk who were aged 35–40 years to provide a 
comparison image that would be available when regular screening 
began at age 40 or older years, but this recommendation was 
dropped in 1992 after a consensus meeting reviewed the evidence 
on screening recommendations and agreed that there was little 
evidence to support a benefit of the baseline screening before 
age 40 years (12). Using data from six counties in California, 
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 Background Few data have been published on mammography performance in women who are younger than 40 years.
 Methods We pooled data from six mammography registries across the United States from the Breast Cancer Surveillance 
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diagnostic mammogram during 1995–2005 and followed them for 1 year to determine accuracy of mammog-
raphy assessment. We measured the recall rate for screening examinations and the sensitivity, specificity, pos-
itive predictive value, and cancer detection rate for all mammograms.
 Results For screening mammograms, no cancers were detected in 637 mammograms for women aged 18–24 years. For 
women aged 35–39 years who had the largest number of screening mammograms (n = 73 335) in this study, the 
recall rate was 12.7% (95% confidence interval [CI] = 12.4% to 12.9%), sensitivity was 76.1% (95% CI = 69.2% to 
82.6%), specificity was 87.5% (95% CI = 87.2% to 87.7%), positive predictive value was 1.3% (95% CI = 1.1% to 
1.5%), and cancer detection rate was 1.6 cancers per 1000 mammograms (95% CI = 1.3 to 1.9 cancers per 1000 
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cancer. For diagnostic mammograms, the age-adjusted rates across all age groups were: sensitivity of 85.7% 
(95% CI = 82.7% to 88.7%), specificity of 88.8% (95% CI = 88.4% to 89.1%), positive predictive value of 14.6% 
(95% CI = 13.3% to 15.8%), and cancer detection rate of 14.3 cancers per 1000 mammograms (95% CI = 13.0 to 
15.7 cancers per 1000 mammograms). Mammography performance, except for specificity, improved in the pres-
ence of a breast lump.
 Conclusions Younger women have very low breast cancer rates but after mammography experience high recall rates, high 
rates of additional imaging, and low cancer detection rates. We found no cancers in women younger than 25 
years and poor performance for the large group of women aged 35–39 years. In a theoretical population of 
10 000 women aged 35–39 years, 1266 women who are screened will receive further workup, with 16 cancers 
detected and 1250 women receiving a false-positive result.
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Kerlikowske et al. (13) reported that the percentage of women re-
ceiving a first screening mammogram between the ages of 30 and 
39 years increased from 21.8% in 1985 to 28.9% in 1992. 
However, still in 2005, 28.9% of US women aged 30–39 years 
reported ever having a mammogram (14). Anecdotal evidence 
suggests that nearly two decades later, some physicians and women 
still believe that a baseline mammogram before age 40 years is 
recommended.
Previous research on mammography use in young women 
has been mainly confined to retrospective examinations of 
mammography and ultrasound data (15) from patients with 
cancer or to examinations of the pathology of the detected can-
cers. Details relating to mammography in young women are 
scarce, with particular gaps in our understanding of who has 
mammography, how accurately mammography is performed, 
and how the outcomes in women younger than 40 years com-
pare with those of women aged 40 years or older, for whom 
regular screening is recommended. We address these issues by 
examining the distribution, performance characteristics, and 
pathological outcomes of first mammographic examination for 
screening or diagnostic purposes among young women receiving 
mammography in community practice in the United States by 




The BCSC is a National Cancer Institute-funded collaborative 
network of population-based mammography registries with link-
ages to pathology and/or tumor registries (16). Analyses in this 
study are based on pooled data from six registries: North Carolina, 
Western Washington State, New Hampshire, New Mexico, San 
Francisco, and Vermont. Each registry links its mammography 
data to its regional or SEER cancer registry for cancer outcomes 
data, including tumor size, stage, and molecular markers. Along 
with the BCSC Statistical Coordinating Center, sites adhere to 
strict confidentiality procedures, comply with the Health Insurance 
Portability and Accountability Act, and have a Federal Certificate 
of Confidentiality and other protection for the identities of women, 
physicians, and facilities who are subjects of this research.
We included 117 738 women from the BCSC who were aged 
18–39 years when they had their first screening or diagnostic 
mammogram during 1995–2005 and followed them for 1 year to 
determine accuracy of mammography assessment. A mammogram 
was determined to be the first if the woman reported no previous 
mammogram at the time of the mammography examination and 
no previous mammogram was found in the registry. We excluded 
women with a history of breast cancer and women with missing 
information on the mammogram interpretation. Mammograms 
were classified according to the radiologists’ recorded indication— 
screening (including 5% where women reported a lump) and/or 
diagnostic—for evaluation of a breast problem (16).
Setting and Participants
Each woman completed a questionnaire at the time of her visit for 
breast imaging that included information on age, race or ethnicity, 
cONteXt AND cAVeAtS
Prior knowledge
Little information is available on the performance of mammog-
raphy in women who are younger than 40 years.
Study design
Data were obtained from six registries on mammography among 
women who were aged 18–39 years at their first mammogram, 
screening or diagnostic. The women were followed for 1 year to 
determine the accuracy of their mammograms, the recall rate for 
screening mammograms, and the sensitivity, specificity, positive 
predictive value, and cancer detection rate for all mammograms.
Contribution
Younger women had very low breast cancer rates but experienced 
high rates of false-positive results, with high recall rates after 
mammography, high rates of additional imaging, and low cancer 
detection rates. No cancers were found in women younger than 
25 years, and poor performance was found for women aged 35– 
39 years.
Implications
Many young women at low or average risk for breast cancer were 
exposed to additional imaging with a low probability of cancer 
detection. Consequently, harms may include additional radiation 
exposure, anxiety associated with false-positive findings, and costs 
associated with additional imaging.
Limitations
There was a sizeable amount of missing data. Complete family 
pedigree or BRCA1 or BRCA2 status could not be collected, and so 
women at very high risk could not be identified.
From the Editors
 
self-reported presence of breast problems, first-degree family 
(ie, first-degree relatives) and personal histories of breast cancer, 
and menopausal status. Radiologists and technologists recorded 
information on imaging performed, indication for the visit, 
breast parenchymal density, mammography interpretation, and 
recommendations for follow-up.
Mammograms were determined to be positive or negative on the 
basis of the interpretation assessment assigned by the radiologist, 
who used the lexicon from the Breast Imaging Reporting and Data 
System (BI-RADS), which scores assessment on a scale of 1–5 with 
increasing probability of cancer and uses a “0” for indeterminate 
studies that need further evaluation. The BI-RADS scores for assess-
ment are 1 = normal; 2 = benign finding; 3 = probably benign; 4 = 
suspicious abnormality; and 5 = suspicious for cancer (17). Previous 
BCSC articles (18,19) describe the use of this scale. An examination 
was positive if the patient was recalled for further assessment or rec-
ommended for biopsy examination (18,19). Standard definitions for 
true-positive, false-positive, true-negative, and false-negative results 
were calculated by use of a 12-month follow-up period (20). Cancers 
in patients were classified as ductal carcinoma in situ or invasive 
cancer; lobular carcinomas in situ were not classified as cancer.
Statistical Analysis
We calculated the following performance measures: recall rate for 
screening (ie, the proportion of screening assessments that led to a 
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recommendation for further workup), sensitivity (ie, the proba-
bility of a positive mammogram assessment, given a cancer was 
detected within 1 year), specificity (ie, the probability of a negative 
mammogram assessment, given no cancer was diagnosed within 
1 year), cancer detection rate (ie, the number of cancers diagnosed 
within 1 year of a positive mammogram per 1000 mammograms), 
screening positive predictive value (ie, the probability of a cancer 
diagnosis within 1 year after a positive screening examination), and 
diagnostic positive predictive value (ie, the probability of cancer, 
given a recommendation for biopsy examination that was based on 
diagnostic mammography) (17).
Performance measures were evaluated separately by indication 
(screening or diagnostic mammography) and stratified by four age 
groups (18–25, 26–29, 30–34, or 35–39 years) for descriptive and 
age characteristics in the performance tables. Measures were strat-
ified by age groups of 18–34 and 35–39 years for assessing family 
history and pathology characteristics because 84.5% of the women 
who received screening mammography were aged 35–39 years 
and because we hypothesized that this unique group most likely 
received mammography for baseline screening, as described above. 
For the remaining characteristics, performance measures were 
age-adjusted via direct standardization. Throughout, 95% confi-
dence intervals (CIs) and P values were estimated by use of a non-
parametric bootstrap method (sampling with replacement from the 
full sample) that was based on 10 000 replications (21). We have 
calculated P values solely for questions related to lump and family 
history because we expected that these variables may have an 
effect among young women, particularly on recall rates, cancer 
rate, and positive predictive value. P values that were calculated 
used a Wald statistic in which the standard error in the denomi-
nator of the test statistic was taken from the bootstrap sampling 
distribution of each statistic and the data were collapsed across 
the groups (ie, under the null hypothesis of no association). 
Pathology characteristics for cancers were reported as counts 
and percentages (based on non-missing counts) separately by 
indication for examination. All statistical tests were two-sided , 
and all analyses were performed with SAS software, version 9.1 
(SAS Institute, Inc, Cary, NC).
results
Descriptive Characteristics and Cancer Rates of Study 
Population
Our study sample included 117 737 women who had received their 
first mammography, 86 781 (73.7%) with a first screening mam-
mogram and 30 956 (26.3%) with a first diagnostic mammogram. 
There were 714 cancers, 188 (26.3%) among first screening mam-
mograms and 526 (73.7%) among first diagnostic mammograms. 
The overall cancer detection rate was 1.6 cancers per 1000 mam-
mograms (95% CI = 1.3 to 1.9 cancers per 1000 mammograms).
First Screening Mammogram. Among the 86 781 young women 
who received screening mammography, 83 862 (96.6%) screening 
mammograms were among women aged 30–39 years, with a 
striking increase in the number of such mammograms starting at 
age 35 years (Figure 1 presents the frequency distribution of mam-
mograms for all women in the Carolina Mammography Registry 
by age). Among the age groups studied, 2919 (3.3%) screened 
women were aged 18–29 years, 10 527 (12.1%) were aged 30–34 
years, and 73 335 (84.5%) were aged 35–39 years. At age 34 years, 
approximately 4000 women were screened compared with approx-
imately 17 000 women at age 35 years.
The racial distribution among screened women was 67.0% 
white, 6.9% African American or African American, and 16.0% 
other (Asian, Alaska Native or American Indian, Hawaiian or 
Pacific Islander, or mixed) (Table 1). Only 3726 (4.3%) of the 
86 781 women aged 18–39 years were menopausal, and 3167 
(3.6%) women reported use of postmenopausal hormone therapy 
at the time of their visit. Overall, a family history of breast cancer 
was reported in 9481 (10.9%) of the 86 871 women who received a 
first screening mammogram, but it was not reported in 67 468 
(77.7%) (data were missing for 9832 women). There was a statisti-
cally significantly higher proportion of positive family history 
among women who were younger than 35 years (26.4%) than 
among those who were aged 35–39 years (8.1%) (P < .001) (Table 
2). Dense breasts were observed in 35 794 (41.2%) women, with 
8957 (10.3%) having extremely dense breasts and 26 837 (30.9%) 
Figure 1. Unadjusted frequency 
distribution of first screening and 
diagnostic mammograms among 
women aged 18–39 years from 
the Breast Cancer Surveillance 
Consortium (1995–2005). Age at 
mammography is shown in years. 
N = number.
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having heterogeneously dense breasts; breast density was missing 
for 27 746 (32.0%) women.
The overall cancer rate in this population was 2.2 cancers diag-
nosed per 1000 mammograms. We observed no cancers in women 
younger than 25 years. The cancer prevalence rate was low (2.1 
cancers per 1000 mammograms) in the oldest age group (ie, 35–39 
years). The overall cancer rate was higher in African American 
women (3.7 cancers per 1000 mammograms) than in white women 
(2.1 cancers per 1000 mammograms) or in women of other races 
(1.5 cancers per 1000 mammograms).
Overall, only 4302 (5.0%) of the 86 781 women self-reported a 
lump at screening, yet they had 49 (26.1%) of the 188 cancers. The 
cancer prevalence rate was 11.4 cancers per 1000 mammograms 
(ie, 49 cancers per 4302 mammograms) among women reporting a 
Table 1. Characteristics of young women having their first mammography, either screening or diagnostic, at ages 18–39 years: Breast 
Cancer Surveillance Consortium
Characteristic
Screening mammography Diagnostic mammography
Mammograms, No. (%) Cancers, No. (%) Mammograms, No. (%) Cancers, No. (%)
Total 86 781 188 30 956 526
Age group, y
 18–24 637 (0.7) 0 (0.0) 1552 (5.0) 5 (1.0)
 25–29 2282 (2.6) 6 (3.2) 4240 (13.7) 38 (7.2)
 30–34 10 527 (12.1) 27 (14.4) 11 361 (36.7) 168 (31.9)
 35–39 73 335 (84.5) 155 (82.4) 13 803 (44.6) 315 (59.9)
Race
 White 58 137 (67.0) 121 (64.4) 20 726 (66.9) 345 (65.6)
 African American 5994 (6.9) 22 (11.7) 2604 (8.4) 72 (13.7)
 Other 13 910 (16.0) 21 (11.2) 4746 (15.3) 71 (13.5)
 Missing 8740 (10.1) 24 (12.8) 2880 (9.3) 38 (7.2)
Family history of breast cancer
 Yes 9481 (10.9) 15 (8.0) 2032 (6.6) 50 (9.5)
 No 67 468 (77.7) 142 (75.5) 25 255 (81.6) 410 (77.9)
 Missing 9832 (11.3) 31 (16.5) 3669 (11.9) 66 (12.5)
Current hormone therapy use
 Yes 3167 (3.6) 9 (4.8) 951 (3.1) 9 (1.7)
 No 76 301 (87.9) 163 (86.7) 27 797 (89.8) 476 (90.5)
 Missing 7313 (8.4) 16 (8.5) 2208 (7.1) 41 (7.8)
Menopausal status
 Yes 3726 (4.3) 10 (5.3) 1143 (3.7) 13 (2.5)
 No 76 473 (88.1) 162 (86.2) 27 372 (88.4) 471 (89.5)
 Missing 6582 (7.6) 16 (8.5) 2441 (7.9) 42 (8.0)
Breast density
 Almost entirely fat 3069 (3.5) 3 (1.6) 1012 (3.3) 9 (1.7)
 Scattered fibroglandular densities 20 172 (23.2) 41 (21.8) 6413 (20.7) 92 (17.5)
 Heterogeneously dense 26 837 (30.9) 70 (37.2) 10 193 (32.9) 194 (36.9)
 Extremely dense 8957 (10.3) 22 (11.7) 4596 (14.8) 80 (15.2)
 Missing 27 746 (32.0) 52 (27.7) 8742 (28.2) 151 (28.7)
Self-reported breast lump
 Yes 4302 (5.0) 49 (26.1) 20 392 (65.9) 455 (86.5)
 No 78 924 (90.9) 127 (67.5) 8884 (28.7) 61 (11.6)
 Missing 3555 (4.1) 12 (6.4) 1680 (5.4) 10 (1.9)
Table 2. Screening mammograms: cancer rate by family history of breast cancer in first-degree relatives and by age group*
Family history of breast cancer in  
first-degree relatives and age group
Screening mammograms,  
No. (%) Cancers, No. (%)
Cancer detection rate, No. of 
cancers per 1000 mammograms 
(95% CI)
Total 86 781 (100.0) 144 (100.0) 1.7 (1.4 to 1.9)
Age 18–34 y 13 446 26 1.9 (1.3 to 2.8)
 Yes 3548 (26.4) 3 (11.5) 0.8 (0.2 to 2.2)
 No 8302 (61.7) 18 (69.2) 2.2 (1.3 to 3.3)
 Missing† 1596 (11.9) 5 (19.2) 3.1 (1.1 to 6.7)
Age 35–39 y 73 335 118 1.6 (1.3 to 1.9)
 Yes 5933 (8.1) 9 (7.6) 1.5 (0.7 to 2.7)
 No 59 166 (80.7) 94 (79.7) 1.6 (1.3 to 1.9)
 Missing† 8236 (11.2) 15 (12.7) 1.8 (1.0 to 2.9)
* CI = confidence interval.
† In some practices, the categories “no” and “missing” were not separated. When we combined the missing and no categories, the percent cancer rate was 
0.8% for a positive family history and 3.0% for a no or missing family history.
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lump, compared with 1.6 cancers per 1000 mammograms (127 
cancers per 78 924 mammograms) among women with no lump 
(P < .001). It is not clear why women who reported a lump had 
screening mammography and not diagnostic mammography.
First Diagnostic Mammography. Among the 30 956 diagnostic 
mammograms identified in this study, women aged 30–39 years 
received 25 164 (81.3%) of them and women aged 18–29 years 
received 5792 (18.7%). A lump at the time of their diagnostic 
mammogram was reported by 20 392 (65.9%) women (Table 1), 
and 14 789 (47.8%) had heterogeneously or very dense 
breasts. Breast density was, however, missing for 8742 (28.2%) 
women. A positive family history of breast cancer was reported 
by only 2032 (6.6%). The overall cancer prevalence rate 
among all diagnostic mammograms was 17.0 cancers per 1000 
mammograms.
Screening Performance
Recall Rate. Recall rates decreased with increasing age, from 
17.6% (95% CI = 14.8% to 20.6%) for the age group 18–24 years 
to 12.7% (95% CI = 12.4% to 12.9%) for the age group 35–39 
years (P < .001) (Table 3). Age-adjusted recall rates were statisti-
cally significantly lower among women with a lump (11.8%, 95% 
CI = 11.6% to 12.1%) than among those without a lump (31.1%, 
95% CI = 29.6% to 32.8%) (P < .001). Women with a family his-
tory of breast cancer had a slightly higher age-adjusted recall rate 
(15.0%, 95% CI = 14.2% to 15.8%) than women without a family 
history of breast cancer (13.5%, 95% CI = 13.2% to 13.8%). 
Recall rates did not differ across racial and/or ethnic groups.
Sensitivity. Age-adjusted sensitivity was 76.5% (95% CI = 70.1% to 
82.5%), and age-specific sensitivity varied by age, with no cancers 
in the age group of 18–24 years (66.7%, 95% CI = 20.0% to 100%, 
in women aged 25–29 years; 81.5%, 95% CI = 65.4% to 95.5%, in 
women aged 30–34 years; and 76.1%, 95% CI = 69.2% to 82.6%, in 
women aged 35–39 years) (Table 3). Age-adjusted sensitivity was 
highest among African American women at 81.2% (95% CI = 62.9% 
to 96.3%) compared with 78.6% (95% CI = 71.0% to 85.8%) among 
white women and 67.0% (95% CI = 42.8% to 88.9%) among women 
of other races. Sensitivity was not associated with breast density or 
with a family history of breast cancer. Age-adjusted sensitivity was 
statistically significantly higher among the 4302 (5.0%) women with 
a lump (84.7%, 95% CI = 73.4% to 94.6%) than among those 
without a lump (74.8%, 95% CI = 66.9% to 82.2%) (P = .022).
Specificity. Age-adjusted specificity was 87.1% (Table 3). 
Specificity increased with increasing age, from 82.4% (95% CI = 
79.4% to 85.2%) in the age group of 18–24 years to 87.5% (95% 
CI = 87.2% to 87.7%) in that of 35–39 years. Specificity was 
higher among women with fatty breasts (91.5%, 95% CI = 90.4% 
to 92.4%) than among women with more dense categories (86%–
89%). Specificity was 19% lower among women with a lump 
Table 3. Recall rate, sensitivity, and specificity for screening and diagnostic mammograms*
Group
Screening mammography Diagnostic mammography
Recall, % (95% CI) Sensitivity, % (95% CI) Specificity, % (95% CI) Sensitivity, % (95% CI) Specificity, % (95% CI)
Total 13.0 (12.8 to 13.2) 76.5 (70.1 to 82.5) 87.1 (86.9 to 87.4) 85.7 (82.7 to 88.7) 88.8 (88.4 to 89.1)
Age group, y
 18–24 17.6 (14.8 to 20.6) 0.0† 82.4 (79.4 to 85.2) 100.0 (100 to 100) 83.8 (81.9 to 85.6)
 25–29 17.1 (15.6 to 18.6) 66.7 (20.0 to 100) 83.0 (81.5 to 84.6) 89.5 (78.6 to 97.7) 88.4 (87.4 to 89.4)
 30–34 14.4 (13.7 to 15.0) 81.5 (65.4 to 95.5) 85.8 (85.1 to 86.4) 86.3 (80.8 to 91.4) 89.5 (88.9 to 90.0)
 35–39 12.7 (12.4 to 12.9) 76.1 (69.2 to 82.6) 87.5 (87.2 to 87.7) 82.5 (78.2 to 86.6) 88.9 (88.4 to 89.5)
Race
 White 13.0 (12.7 to 13.3) 78.6 (71.0 to 85.8) 87.2 (86.9 to 87.4) 86.6 (82.9 to 90.0) 89.5 (89.1 to 89.9)
 African American 13.7 (12.8 to 14.5) 81.2 (62.9 to 96.3) 86.5 (85.7 to 87.4) 81.5 (71.5 to 90.0) 87.9 (86.6 to 89.2)
 Other 12.6 (12.0 to 13.1) 67.0 (42.8 to 88.9) 87.5 (87.0 to 88.1) 89.0 (80.7 to 95.7) 85.6 (84.6 to 86.6)
Family history of  
  breast cancer
 No 13.5 (13.2 to 13.8) 78.8 (71.7 to 85.4) 86.6 (86.4 to 86.9) 85.4 (81.9 to 88.8) 88.6 (88.2 to 89.0)
 Yes 15.0 (14.2 to 15.8) 78.7 (51.5 to 100.0) 85.1 (84.3 to 85.9) 78.1 (65.1 to 89.9) 87.0 (85.5 to 88.4)
Breast density
 Almost entirely fat 8.6 (7.6 to 9.6) 66.7 (0.0 to 100) 91.5 (90.4 to 2.4) 100.0‡ 93.2 (91.6 to 94.7)
 Scattered  
  fibroglandular  
  densities
13.9 (13.4 to 14.4) 82.9 (70.1 to 93.8) 86.2 (85.8 to 86.7) 87.1 (77.1 to 94.5) 91.3 (90.6 to 92.0)
 Heterogeneously  
  dense
14.7 (14.2 to 15.1) 72.9 (61.8 to 83.2) 85.5 (85.1 to 85.9) 85.9 (80.5 to 90.9) 88.1 (87.4 to 88.7)
 Extremely dense 11.4 (10.8 to 12.1) 73.7 (54.8 to 91.7) 88.7 (88.1 to 89.4) 77.9 (68.9 to 86.4) 89.2 (88.3 to 90.1)
Self-reported breast  
  lump
 No 11.8 (11.6 to 12.1) 74.8 (66.9 to 82.2) 88.3 (88.0 to 88.5) 71.5 (59.8 to 82.7) 93.0 (92.5 to 93.6)
 Yes 31.1 (29.6 to 32.8) 84.7 (73.4 to 94.6) 69.6 (68.0 to 71.2) 87.5 (84.3 to 90.5) 86.6 (86.2 to 87.1)
* CI = confidence interval.
† There were only three cancers and we did not calculate the confidence interval.
‡ Only three cancers were observed; insufficient information is available to calculate a reliable point estimate and 95% confidence interval.
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(69.6%, 95% CI = 68.0% to 71.2%) than among women without a 
lump (88.3%, 95% CI = 88.0% to 88.5%) (P < .001). Specificity was 
not associated with race or with family history of breast cancer.
Positive Predictive Value of Screening Mammography. Age-
adjusted positive predictive value of screening was 1.3% (95% 
CI = 1.1% to 1.5%), with a slight variation with age (Table 4). 
Positive predictive value of screening was 3.7% (95% CI = 2.5% to 
4.9%) among women with a self-reported lump compared with 
1.0% (95% CI = 0.8% to 1.2%) among women without a lump 
(P < .001). A higher positive predictive value of screening was 
observed among African American women than among white 
women, and a statistically significantly higher positive predictive 
value was observed among women with a positive family history 
(1.2%, 95% CI = 1.0% to 1.5%) than among women without such 
history (0.9%, 95% CI = 0.4% to 1.5%) (P = .032).
Cancer Detection Rate per 1000 Mammograms. The overall 
age-adjusted cancer detection rate was 1.7 cancers per 1000 mam-
mograms (95% CI = 1.4 to 1.9 cancers per 1000 mammograms). 
The cancer detection rate essentially did not change with age and 
was not associated with family history, particularly in the age 
group of 35–39 years (Table 2). African American women had 
higher cancer detection rates than white women. The cancer de-
tection rate was higher among women with a lump (11.4 cancers 
per 1000 mammograms, 95% CI = 7.8 to 15.4) than among women 
without a lump (1.2 cancers per 1000 mammograms, 95% CI = 1.0 
to 1.4) (P < .001).
Diagnostic Performance
Sensitivity. Age-adjusted diagnostic sensitivity was high (85.7%, 
95% CI = 82.7% to 88.7%) (Table 3). Sensitivity was higher 
among women who reported a lump (87.5%, 95% CI = 84.3% to 
90.5%) than among women who reported other symptoms (71.5%, 
95% CI = 59.8% to 82.7%) (P = .001). Sensitivity was lower among 
African American women (81.5%, 95% CI = 71.5% to 90.0%) 
than among white women (86.6%, 95% CI = 82.9% to 90.0%) or 
women of other races (89.0%, 95% CI = 80.7% to 95.7%).
Specificity. Age-adjusted specificity was 88.8% (95% CI = 88.4% 
to 89.1%) and was not influenced by family history or race. 
Specificity was lower in the youngest age group, 18–24 years 
(83.8%, 95% CI = 81.9% to 85.6%), than in the other three age 
groups (88%–90%) and was lower among women who reported a 
lump (86.6%, 95% CI = 86.2% to 87.1%) than among those who 
did not (93.0%, 95% CI = 92.5% to 93.6%) (P < .001). Across the 
levels of breast density, specificity was highest among women 
with fatty breasts (93.2%, 95% CI = 91.6% to 94.7%) and decreased 
with increasing breast density (91.3% scattered fibroglandular den-
sities, 88.1% heterogeneously dense and 89.2% extremely dense).
Positive Predictive Values of Diagnostic Mammography. The 
age-adjusted positive predictive value for diagnostic mammog-
raphy was 14.6% (95% CI = 13.3% to 15.8%) (Table 4). The 
positive predictive value of diagnostic mammography increased 
with each age group from 2.3% (95% CI = 0.5% to 4.5%) in those 
aged 18–24 years to 18.6% (95% CI = 16.6% to 20.6%) in those 
Table 4. Positive predictive values and cancer detection rates for screening and diagnostic mammograms*
Characteristic
Screening mammography (cancer prevalence =  
2.2 cancers per 1000 mammograms)
Diagnostic mammography (cancer prevalence = 
17.0 cancers per 1000 mammograms)
PPV1, % (95% CI)
Cancer detection rate, No. per  
1000 mammograms (95% CI) PPV2, % (95% CI)
Cancer detection rate, No. per 
1000 mammograms (95% CI)
Total 1.3 (1.1 to 1.5) 1.7 (1.4 to 1.9) 14.6 (13.3 to 15.8) 14.3 (13.0 to 15.7)
Age group, y
 18–24 0.0† 0.0† 2.3 (0.5 to 4.5) 3.2 (0.6 to 6.4)
 25–29 1.0 (0.2 to 2.1) 1.8 (0.4 to 3.5) 8.0 (5.5 to 10.6) 8.0 (5.4 to 10.8)
 30–34 1.5 (0.9 to 2.1) 2.1 (1.2 to 3.0) 13.8 (11.8 to 16.0) 12.8 (10.7 to 14.9)
 35–39 1.3 (1.1 to 1.5) 1.6 (1.3 to 1.9) 18.6 (16.6 to 20.6) 18.8 (16.5 to 21.1)
Race
 White 1.3 (1.0 to 1.5) 1.6 (1.3 to 2.0) 15.2 (13.6 to 16.8) 14.0 (12.4 to 15.6)
 African American 1.9 (1.1 to 2.9) 2.6 (1.4 to 4.0) 18.1 (14.0 to 22.4) 23.5 (17.7 to 29.8)
 Other 0.8 (0.4 to 1.3) 1.1 (0.6 to 1.6) 10.6 (8.1 to 13.3) 13.0 (9.8 to 16.4)
Family history of breast  
  cancer
 No 1.2 (1.0 to 1.5) 1.7 (1.4 to 2.0) 13.9 (12.5 to 15.2) 13.5 (12.1 to 15.0)
 Yes 0.9 (0.4 to 1.5) 1.4 (0.6 to 2.3) 18.2 (13.1 to 23.4) 20.4 (14.2 to 27.0)
Breast density
 Almost entirely fat 0.8 (0.0 to 2.1) 0.6 (0.0 to 1.6) 15.8 (6.7 to 26.2) 9.0 (3.9 to 15.0)
 Scattered fibroglandular  
  densities
1.2 (0.8 to 1.6) 1.7 (1.1 to 2.3) 15.0 (12.1 to 18.0) 12.4 (9.8 to 15.2)
 Heterogeneously dense 1.3 (0.9 to 1.7) 1.9 (1.4 to 2.4) 15.4 (13.3 to 17.6) 16.0 (13.6 to 18.5)
 Extremely dense 1.6 (0.9 to 2.4) 1.8 (0.9 to 2.7) 14.9 (11.5 to 18.4) 13.9 (10.6 to 17.5)
Self-reported breast lump
 No 1.0 (0.8 to 1.2) 1.2 (1.0 to 1.4) 8.3 (6.0 to 10.6) 4.7 (3.4 to 6.2)
 Yes 3.7 (2.5 to 4.9) 11.4 (7.8 to 15.4) 16.2 (14.8 to 17.7) 19.5 (17.7 to 21.5)
* CI = confidence interval; PPV1 = screening positive predictive value; PPV2 = diagnostic positive predictive value.
† There were no cancers, thus we did not calculate confidence intervals.
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aged 35–39 years and was statistically significantly higher among 
women with a lump (16.2%, 95% CI = 14.8% to 17.7%) than 
among women without a lump (8.3%, 95% CI = 6.0% to 10.6%) 
(P < .001). In addition, this value was lower (10.6%, 95% CI = 
8.1% to 13.3%) among women in the other racial group than 
among African American women (18.1%, 95% CI = 14.0% to 
22.4%) and among white women (15.2%, 95% CI = 13.6% to 
16.8%).
Cancer Detection Rate per 1000 Mammograms. Overall, the 
age-adjusted cancer detection rate was 14.3 cancers detected per 
1000 mammograms (95% CI = 13.0 to 15.7). It was higher for 
African American women (23.5 cancers detected per 1000 mam-
mograms, 95% CI = 17.7 to 29.8) than for white women (14.0 
cancers detected per 1000 mammograms, 95% CI = 12.4 to 15.6) 
or women of other races (13.0 cancers detected per 1000 mammo-
grams, 95% CI = 9.8 to 16.4). Women with a positive family his-
tory of breast cancer (20.4 cancers detected per 1000 mammograms, 
95% CI = 14.2 to 27.0) had a higher cancer detection rate than 
those without such a family history (13.5 cancers detected per 1000 
mammograms, 95% CI = 12.1 to 15.0). Women who reported a 
lump had a higher cancer detection rate (19.5 cancers detected per 
1000 mammograms, 95% CI = 17.7 to 21.5) than women who did not 
(4.7 cancers detected per 1000 mammograms, 95% CI = 3.4 to 6.2).
Pathological Results From Screening Mammography
In this study population, no cancers were diagnosed after a first 
screening mammogram among women aged 18–24 years (Table 5). 
Tumor characteristics of women aged 25–34 years were associated 
with poorer prognosis than those of women aged 35–39 years, 
including a higher proportion of invasive cancers (81.8% vs 70.3%, 
respectively), stage II or higher (45.4% vs 39.3%), poorly differen-
tiated or undifferentiated (54.5% vs 47.1%), greater than 2 cm 
(39.4% vs 32.9%), estrogen receptor negative and progesterone 
receptor negative (30.3% vs 20.6%), and positive lymph nodes 
(45.4% vs 29.7%).
Pathological Results From Diagnostic Mammography
Women aged 18–34 years, compared with those aged 35–39 
years, had higher proportions of invasive cancers (94.8% vs 91.1%, 
Table 5. Tumor characteristics among young women aged 18–39 years who were undergoing their first mammography*
Characteristic
Screening mammography, No. (%)† Diagnostic mammography, No. (%)†
≤34 y 35–39 y ≤34 y 35–39 y
Total 33 155 211 315
Cancer type
 Ductal carcinoma in situ 6 (18.2) 46 (29.7) 11 (5.2) 28 (8.9)
 Invasive 27 (81.8) 109 (70.3) 200 (94.8) 287 (91.1)
Stage
 0 6 (18.2) 46 (29.7) 11 (5.2) 28 (8.9)
 I 5 (15.2) 30 (19.3) 52 (24.6) 86 (27.3)
 II 8 (24.2) 43 (27.7) 88 (41.7) 116 (36.8)
 III 7 (21.2) 15 (9.7) 27 (12.8) 44 (14.0)
 IV 0 (0.0) 3 (1.9) 7 (3.3) 14 (4.4)
 Missing‡ 7 (21.2) 18 (11.6) 26 (12.3) 27 (8.6)
Grade
 Well differentiated 1 (3.0) 13 (8.4) 7 (3.3) 25 (7.9)
 Moderately differentiated 8 (24.2) 41 (26.4) 54 (25.6) 89 (28.3)
 Poorly differentiated 17 (51.5) 65 (41.9) 98 (46.4) 146 (46.3)
 Undifferentiated 1 (3.0) 8 (5.2) 18 (8.5) 17 (5.4)
 Missing‡ 6 (18.2) 28 (18.1) 34 (16.1) 38 (12.1)
Tumor size, mm
 0–5 1 (3.0) 15 (9.7) 11 (5.2) 13 (4.1)
 6–10 3 (9.1) 15 (9.7) 14 (6.6) 28 (8.9)
 11–20 6 (18.2) 43 (27.7) 69 (32.7) 102 (32.4)
 21–50 10 (30.3) 44 (28.4) 73 (34.6) 118 (37.5)
 ≥51 3 (9.1) 7 (4.5) 17 (8.1) 16 (5.1)
 Missing‡ 10 (30.3) 31 (20.0) 27 (12.8) 38 (12.1)
ER–PR status
 Positive–positive 11 (33.3) 45 (29.0) 79 (37.4) 121 (38.4)
 Positive–negative 0 (0.0) 8 (5.2) 16 (7.6) 18 (5.7)
 Negative–positive 0 (0.0) 0 (0.0) 5 (2.4) 13 (4.1)
 Negative–negative 10 (30.3) 32 (20.6) 50 (23.7) 67 (21.3)
 Missing‡ 12 (36.4) 70 (45.2) 61 (28.9) 96 (30.5)
Lymph node status
 Positive 15 (45.4) 46 (29.7) 93 (44.1) 143 (45.4)
 Negative 16 (48.5) 101 (65.2) 109 (51.6) 166 (52.7)
 Missing‡ 2 (6.1) 8 (5.2) 9 (4.3) 6 (1.9)
* ER = estrogen receptor; PR = progesterone receptor.
† Percentage of non-missing values.
‡ Percentage of total values.
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respectively), cancers that were stage II or higher (57.8% vs 
55.2%), poorly differentiated or undifferentiated cancers (54.9% 
vs 51.7%), and estrogen receptor–negative and progesterone 
receptor–negative cancers (23.7% vs 21.3%). However, we 
observed little difference between the two age groups in the pro-
portion of cancers that were greater than 2 cm in diameter (42.7% 
vs 42.6%) or proportion of patients with positive lymph nodes 
(44.1% vs 45.4%).
Discussion
To our knowledge, this study was the first comprehensive 
community-based evaluation of the first mammography experi-
ence, including both screening and diagnostic mammography, 
among women younger than 40 years. In our population, a sub-
stantial percentage of young women received screening mammog-
raphy, but few breast cancers were found, regardless of their 
specific age, race, or individual characteristics. Yet, these women 
experience high recall rates with high rates of additional imaging. 
The sensitivity, specificity, and screening positive predictive value 
of screening mammography were poor, and cancer detection rates 
were very low in these young women, who are not yet in an age 
group for which national organizations recommend regular 
screening mammography. Harms need to be considered, including 
radiation exposure because such exposure is more harmful in 
young women (22,23), the anxiety associated with false-positive 
findings on the initial examination, and costs associated with addi-
tional imaging. If we consider a theoretical population of 10 000 
women aged 35–39 years, then from our results, an average of 
1266 women who are screened will receive further workup, with 
16 cancers being detected and 1250 false-positive examinations. 
This cancer detection rate corresponds to an estimated 79 workups 
for each cancer detected. Using the same methods that were out-
lined above, we also considered two theoretical populations of 
women who underwent their first mammography at the ages of 
40–44 years or 45–49 years. The number of workups per cancer 
detected was estimated to be 66 in the age group of 40–44 years 
and 40 in the age group of 45–49 years. Performance characteris-
tics were good for diagnostic mammography, as expected because 
most young women undergoing diagnostic mammography reported 
the presence of a breast lump and because diagnostic mammog-
raphy performance improved when a lump was reported.
It is unclear why the first mammogram for some women with a 
breast lump was classified as a screening mammogram, and for 
others, it was classified as a diagnostic mammogram. Women 
reporting a breast lump constituted a small proportion of the 
screening mammography population (5%) but were different from 
the women reporting a lump in the diagnostic mammography 
population (ie, the specificity and the cancer detection rate among 
women with a lump who received a screening mammogram was 
observed to be lower than that among women with a lump who 
received diagnostic mammography). Unfortunately, we could not 
evaluate when the lumps were detected. For example, it is possible 
that among women with a breast lump, some made a screening 
appointment and then developed a lump that was then reported at 
the time of screening, whereas others with a lump may have sought 
an immediate consultation for a new breast symptom, without 
having scheduled a mammogram. The subgroup of women 
arriving for screening with a lump need further study because they 
appear to be a clinically distinct group.
The majority of women who were younger than 40 years at 
their first screening mammogram (67 468 [77.7%]) had no family 
history of breast cancer in a first-degree relative, in particular 
women aged 35–39 years (80.7%). We caution against screening 
young women with a positive family history of breast cancer, 
unless there are characteristics that are associated with an inherited 
predisposition to breast cancer at a very young age; we make this 
recommendation because performance characteristics were similar 
in women with a family history of breast cancer and in women 
without such history. Women with a family history of breast can-
cer, compared with those without such history, had higher recall 
rates but equal cancer rates and cancer detection rates. Some 
women and/or their providers may be requesting a baseline mam-
mogram, most likely a holdover from historical American Cancer 
Society guidelines (12,24). It is also possible that the women and/
or their providers think that they are at high risk and can benefit 
from screening. Kapp et al. (25) used data from the National 
Health Interview Survey and found that women aged 35–39 years 
who had a mammogram reported a physician recommendation 
for a mammogram regardless of risk factors. Risk factors, however, 
were more likely to explain reported phyisician recommendations 
for mammography for women aged 30–34 years.
To understand the level of performance reported in this study, 
we compared these results in young women (aged 18–39 years) 
with results from women in the BCSC who were aged 40–44 years 
and 45–49 years and who had their first screening mammogram in 
the BCSC. Mammography performance measures in young 
women (aged 18–39 years), except for specificity, were inferior to 
those in women aged 40–49 years. Age-adjusted sensitivity of first 
screening mammography was lower among young women (76.5%) 
than among women aged 40–44 years (82.4%) or 45–49 years 
(87.3%). The cancer detection rate among women aged 18–39 
years was 1.7 cancers per 1000 mammograms, among those aged 
40–44 years was 2.3 cancers per 1000 mammograms, and among 
women aged 45–49 years was 4.3 cancers per 1000 mammograms. 
This cancer detection rate in young women may be higher than 
expected in comparison to incidence rates because data were from 
first mammograms. The poor performance of screening mammog-
raphy among younger women is likely attributed to the very low 
cancer prevalence in this group. Most of the young women have 
dense parenchymal tissue that may mask tumors, and so breast 
density may also contribute to the lower performance of mammog-
raphy in young women.
Consistent with previously published work (3,26), pathology 
results indicated that tumors from most young women compared 
with tumors from older women have poorer prognostic character-
istics, higher stage, higher proportion of positive lymph nodes, and 
higher proportion with an estrogen receptor–negative and proges-
terone receptor–negative status. Although the young women in 
our population had a higher proportion of cancers with poor prog-
nostic characteristics, they also had poor mammography perfor-
mance indicators with low sensitivity, specificity, and cancer 
detection rate. These results pose challenges to screening decisions. 
African American women have higher cancer rates and poorer 
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outcomes than white women (27–30). Young African American 
women are screened at a higher rate than white women (31), which 
could be explained by physicians giving greater importance to the 
relative risk of a diagnosis before age 40 years than to the absolute 
risk and by the perception that because a high level of cancers with 
poor prognosis are found among young African American women, 
earlier screening is required for this group (32). Our findings 
support a need for serious discussion about the appropriateness of 
mammography in women without the presence of symptoms. The 
results for diagnostic mammography are much better for all 
young women perhaps because 70% report the presence of a 
lump at the time of testing. Symptomatic women should receive 
mammography.
Few community-based studies have been conducted to evaluate 
the performance of mammography among young women. The 
Oregon Breast and Cervical Cancer Program (BCCP), which tar-
geted women at the poverty level, has reported that 21% of women 
who were younger than 40 years were asymptomatic but that 79% 
of their women who were sent mammography had been examined 
for a breast problem, which is a much smaller proportion than 
were examined by screening in our population (33). Discrepancies 
between that study and this study might be that data for this study 
were from all women in participating practices, whereas data in the 
BCCP study were from women who were eligible for that study 
(ie, those with incomes of up to 250% of the Federal Poverty Level 
and who were uninsured or underinsured). Thus, mammographic 
screening of asymptomatic women is not supported and should be 
reserved for young women with symptoms.
Breast ultrasound and breast magnetic resonance imaging are 
increasingly used in young women (34), yet to date there are no 
community-based evaluations of the performance characteristics 
or demonstrations of a reduction in morbidity and mortality. Both 
of these modalities would be important in lowering the radiation 
dose to young women.
This study has several limitations. First, because our data reflect 
clinical practice, we had a sizeable amount of missing data for 
breast density and pathology characteristics. Density data are 
largely missing as a result of practice-specific nonreporting, and 
pathology characteristics are missing when they are not reported 
on the pathology reports to the cancer registries and/or are specific 
to a hospital or pathology laboratory. Second, we could not collect 
the complete family pedigree or BRCA1 or BRCA2 status of those 
in our study, which prevents us from identifying women at very 
high risk. Finally, we do not know the outmigration of women 
from the region in which they were diagnosed within 12 months of 
their mammogram. This percentage is expected to be small, and 
most women with a positive mammogram complete their workup 
within a month. The major strengths of our study include the 
representative community-based nature of the BCSC, the large 
sample size, and prospective cancer follow-up through linkages 
with local registry and/or pathology databases.
Future research should explore the association of symptoms 
with accuracy and health-seeking behavior. In addition, research 
should provide guidance on defining which young women might 
benefit from screening mammography and on the role and use 
of advanced technologies to detect breast cancers in younger 
women.
In conclusion, young women have received screening mam-
mography, but few cancers have been detected, regardless of their 
specific age, race, or other individual characteristics. With high 
recall and low cancer detection rates, many young women, who are 
at low or average risk for breast cancer, are having additional im-
aging as a result of undergoing screening mammography, with a 
low probability of cancer detection. Who should be screened for 
breast cancer at younger ages and how best to screen them remain 
important research questions. Cancers in young women, across the 
board, have characteristics associated with more rapid tumor 
growth and poorer prognosis than those in older women. Tumor 
characteristics with poorer prognostic characteristics pose a di-
lemma: It is important to find breast cancers in young women early 
because of the underlying tumor biology of such cancers; yet 
current screening performance is challenged by the high breast 
density, which is generally found in young women. Research 
results evaluating the performance of the addition of ultrasound 
and/or breast magnetic resonance imaging in young women at 
high risk for breast cancer are needed to show whether these 
modalities perform better than mammography alone in young 
women.
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